Berdeja JG et al. Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (Pts) with multiple myeloma who are not candidates for high dose chemotherapy. Proc ASH 2013;122(21);Abstract 3193.

Dytfeld D et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica 2014;99(9):e162-4. Abstract

Ludwig H et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist 2014;19(8):829-44. Abstract

Palumbo A et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report. Blood 2015;125(13):2068-74. Abstract

Quach H et al. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Intern Med J 2015;45(3):335-43. Abstract

Stewart AK et al. Melphalan, prednisone and thalidomide versus melphalan, prednisone and lenalidomide (ECOG: E1A06) in untreated multiple myeloma. Blood 2015;[Epub ahead of print]. Abstract

Wildes TM et al. Multiple myeloma in the older adult: Better prospects, more challenges. J Clin Oncol 2014;32(24):2531-40. Abstract